|
US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
|
BE788065A
(fr)
|
1971-08-26 |
1973-02-26 |
Degussa |
Nouvelles aza-benzimidazoles et procede pour leur preparation
|
|
IT1156732B
(it)
|
1978-05-10 |
1987-02-04 |
Roussel Maestretti Spa |
Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
|
|
US4668686A
(en)
|
1985-04-25 |
1987-05-26 |
Bristol-Myers Company |
Imidazoquinoline antithrombrogenic cardiotonic agents
|
|
US4775674A
(en)
|
1986-05-23 |
1988-10-04 |
Bristol-Myers Company |
Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
|
|
US4943573A
(en)
|
1989-11-01 |
1990-07-24 |
Bristol-Myers Squibb Company |
Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
|
|
US5354759A
(en)
|
1991-09-12 |
1994-10-11 |
Fujisawa Pharmaceutical Co., Ltd. |
Angiotenin II antagonizing heterocyclic compounds
|
|
JPH0641135A
(ja)
|
1992-07-21 |
1994-02-15 |
Nippon Soda Co Ltd |
イミダゾプテリジン誘導体及びその製造方法
|
|
US6162804A
(en)
|
1997-09-26 |
2000-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6232320B1
(en)
|
1998-06-04 |
2001-05-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
|
SK18542000A3
(sk)
|
1998-06-04 |
2001-12-03 |
Abbott Laboratories |
Protizápalové zlúčeniny inhibujúce bunkovú adhéziu
|
|
KR100756592B1
(ko)
|
1999-10-08 |
2007-09-10 |
그뤼넨탈 게엠베하 |
비사이클릭 이미다조-3-일-아민 유도체, 이의 제조방법 및 이를 포함하는 진통제
|
|
CN1211385C
(zh)
|
1999-10-08 |
2005-07-20 |
格吕伦塔尔有限公司 |
双环咪唑－5－基胺衍生物
|
|
DE10050663A1
(de)
|
2000-10-13 |
2002-04-18 |
Gruenenthal Gmbh |
Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
|
|
US20040235801A1
(en)
*
|
2001-10-25 |
2004-11-25 |
Jean-Pierre Julien |
Therapy for stroke
|
|
US20030083318A1
(en)
*
|
2001-10-25 |
2003-05-01 |
Jean-Pierre Julien |
Therapy for neurodegenerative diseases
|
|
GB0206860D0
(en)
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Compounds
|
|
GB0212048D0
(en)
|
2002-05-24 |
2002-07-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU2003294249A1
(en)
|
2002-11-08 |
2004-06-03 |
Trimeris, Inc. |
Hetero-substituted benzimidazole compounds and antiviral uses thereof
|
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
ATE461196T1
(de)
|
2003-06-26 |
2010-04-15 |
Merck Sharp & Dohme |
Benzodiazepin-cgrp-rezeptor-antagonisten
|
|
CA2530081A1
(en)
|
2003-07-01 |
2005-01-13 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
MXPA06007054A
(es)
|
2003-12-19 |
2007-04-17 |
Elixir Pharmaceuticals Inc |
Metodos para tratar una enfermedad.
|
|
CA2553670A1
(en)
|
2004-01-29 |
2005-08-11 |
Elixir Pharmaceuticals, Inc. |
Anti-viral therapeutics
|
|
WO2005108374A1
(en)
|
2004-04-29 |
2005-11-17 |
Fmc Corporation |
Insecticidal diazole and triazole derivatives
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
JP2008514628A
(ja)
|
2004-09-24 |
2008-05-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
蛋白質キナーゼ類のイミダゾ｛４，５−ｂ｝ピラジノン阻害剤
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
WO2006088836A2
(en)
|
2005-02-16 |
2006-08-24 |
Schering Corporation |
Piperazine-piperidines with cxcr3 antagonist activity
|
|
US7718657B2
(en)
|
2005-12-16 |
2010-05-18 |
Cytokinetics, Inc. |
Certain indanyl urea modulators of the cardiac sarcomere
|
|
EP2037931A2
(en)
|
2006-04-25 |
2009-03-25 |
Astex Therapeutics Limited |
Pharmaceutical combinations of pk inhibitors and other active agents
|
|
EP2043655A2
(en)
|
2006-04-25 |
2009-04-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
US8227603B2
(en)
*
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
|
WO2008016648A2
(en)
|
2006-08-01 |
2008-02-07 |
Cytokinetics, Incorporated |
Certain chemical entities, compositions and methods
|
|
CN101522681B
(zh)
*
|
2006-08-02 |
2012-10-03 |
赛特凯恩蒂克公司 |
特定的化学个体、组合物和方法
|
|
RS54542B1
(en)
|
2006-08-02 |
2016-06-30 |
Cytokinetics, Inc. |
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE
|
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
|
CL2007002994A1
(es)
|
2006-10-19 |
2008-02-08 |
Wyeth Corp |
Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
|
|
ATE543819T1
(de)
|
2006-10-19 |
2012-02-15 |
Signal Pharm Llc |
Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
|
|
WO2008075007A1
(en)
|
2006-12-21 |
2008-06-26 |
Cancer Research Technology Limited |
Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
|
|
WO2008089459A1
(en)
|
2007-01-19 |
2008-07-24 |
Ardea Biosciences, Inc. |
Inhibitors of mek
|
|
US7851484B2
(en)
|
2007-03-30 |
2010-12-14 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2018854A1
(en)
|
2007-07-27 |
2009-01-28 |
Merz Pharma GmbH & Co. KGaA |
Novel combinations of neramexane for the treatment of neurodegenerative disorders
|
|
US7998976B2
(en)
|
2008-02-04 |
2011-08-16 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
|
CA2713864A1
(en)
|
2008-02-04 |
2009-08-13 |
Cytokinetics, Incorporated |
Certain chemical entities, compositions and methods
|
|
WO2010004031A2
(en)
*
|
2008-07-11 |
2010-01-14 |
Glaxo Group Limited |
Novel treatment
|
|
CA2744498C
(en)
|
2008-11-25 |
2017-10-24 |
University Of Rochester |
Mlk inhibitors and methods of use
|
|
EP2228054A1
(en)
|
2009-03-13 |
2010-09-15 |
ITALFARMACO S.p.A. |
Riluzole aqueous suspensions
|
|
AU2010262970A1
(en)
|
2009-06-19 |
2012-01-12 |
Knopp Neurosciences, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
BR112014024552A2
(pt)
|
2012-04-02 |
2017-09-19 |
Cytokinetics Inc |
método para aprimorar a função do diafragma em um paciente que necessite do mesmo; método para aumentar a função, atividade, eficiência, sensibilidade ao cálcio ou tempo de fadiga do músculo esquelético no diafragma de um paciente que necessite do mesmo e método para aumentar a função, atividade, eficiência, força, sensibilidade ao cálcio ou tempo de fadiga de uma fibra muscular esquelética do diafragma.
|
|
EP2836590A4
(en)
|
2012-04-11 |
2016-04-13 |
Cytokinetics Inc |
METHOD FOR IMPROVING THE RESISTANCE TO SKELETON MUSCULAR FEEDING
|
|
DK3137622T3
(da)
|
2014-04-29 |
2022-02-07 |
Cytokinetics Inc |
Fremgangsmåder til at reducere tilbagegang af vitalkapacitet
|
